Merck KGaA (OTCMKTS:MKGAF) Sees Strong Trading Volume - Here's Why

Key Points

• Trading spike: Shares saw 680 shares change hands on Monday (a 13% increase from 604) and last traded at $133.835, about 1.1% higher than the prior close of $131.15.
• Valuation and key metrics: Merck KGaA has a market cap of $17.14 billion, a P/E of 20.25, beta 0.96, quick ratio 0.84, current ratio 1.31, debt-to-equity 0.27, and 50-/200-day SMAs of $133.88 and $139.42.
• Company profile: Headquartered in Darmstadt, Germany, Merck KGaA is a centuries-old multinational chemical and pharmaceutical group (founded 1668) privately controlled by the Merck family and organized into three main business units serving global markets.

Shares of Merck KGaA (OTCMKTS:MKGAF - Get Free Report) saw strong trading volume on Monday . 680 shares changed hands during trading, an increase of 13% from the previous session's volume of 604 shares.The stock last traded at $133.8350 and had previously closed at $131.15.

Merck KGaA Trading Up 1.1%

The firm has a market cap of $17.14 billion, a P/E ratio of 20.25 and a beta of 0.96. The company has a quick ratio of 0.84, a current ratio of 1.31 and a debt-to-equity ratio of 0.27. The firm's 50-day simple moving average is $133.88 and its 200 day simple moving average is $139.42.

About Merck KGaA

Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.

The company's operations are organized mainly into three businesses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.